High-Bleeding Risk

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up
Aspirin-Free Strategy in High Bleeding Risk PCI Patients: Insights from STOPDAPT-3 Subgroup Analysis
Comparing Cardiac MRI and Coronary Angiography for Diagnosing Ischemic Cardiomyopathy in New-Onset Heart Failure
Intranasal Mesenchymal Stromal Cells for Perinatal Arterial Stroke: Promising Safety and Improved Neurodevelopment at Two Years
RNS60 as Adjunctive Therapy in Acute Large Vessel Occlusion Stroke: Insights from the RESCUE Trial

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

aging AI artificial intelligence blood pressure breast cancer béo phì cardiovascular health cardiovascular risk clinical trial COPD COVID-19 diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity MASH mental health metformin Mortality nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch thử nghiệm lâm sàng tirzepatide type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Scroll to Top